Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Houston N. Gilbert"'
Autor:
James Ziai, Houston N Gilbert, Oded Foreman, Jeffrey Eastham-Anderson, Felix Chu, Mahrukh Huseni, Jeong M Kim
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0190158 (2018)
The prevalence of cytotoxic tumor infiltrating lymphocytes (TILs) has demonstrated prognostic value in multiple tumor types. In particular, CD8 counts (in combination with CD3 and CD45RO) have been shown to be superior to traditional UICC staging in
Externí odkaz:
https://doaj.org/article/23c3a93c2955433186b3b129c97d077b
Autor:
Vicky, Makker, Fernando O, Recio, Ling, Ma, Ursula A, Matulonis, Jennifer O, Lauchle, Hema, Parmar, Houston N, Gilbert, Joseph A, Ware, Rui, Zhu, Shan, Lu, Ling-Yuh, Huw, Yulei, Wang, Hartmut, Koeppen, Jill M, Spoerke, Mark R, Lackner, Carol A, Aghajanian
Publikováno v:
Cancer. 122(22)
The current single-arm, open-label trial was designed to evaluate the activity of apitolisib (GDC-0980), a dual phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor, in patients with advanced endometrial cancer (EC).Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::66d4dda3d6f50afcb807608cdf97bbea
https://pubmed.ncbi.nlm.nih.gov/27603005
https://pubmed.ncbi.nlm.nih.gov/27603005
Autor:
Mac Reiter, Keith Pitts, Donald P. Huddler, Houston N. Gilbert, Brandon J. Bravo, Chris Strande, Anthony M. Giannetti
Publikováno v:
Fragment-Based Drug Discovery ISBN: 9781849739085
The development and adoption of fragment-based lead discovery is partly driven by the deployment and refinement of the technologies that enable this drug-discovery approach. Advances in the capabilities of the core discovery functions have historical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82aa4c7b535ff040a4ae707d829acfca
https://doi.org/10.1039/9781782620938-00019
https://doi.org/10.1039/9781782620938-00019
